Ming Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ming Zhou has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Rajal B. Shah
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
16 shared publications Fang-Ming Deng
Department of Pathology New York University Langone Medical Center New York NY USA
8 shared publications- Jonathan Melamed
Department of Pathology, New York University Langone Medical Center, New York, NY
8 shared publications - Anil Vasdev Parwani
Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
3 shared publications Rajal B. Shah
Department of Pathology University of Texas Southwestern Medical Center Dallas TX USA
3 shared publications- Abu Shahin
Department of Rheumatology Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh
2 shared publications
Latest Publications
- 8 November 2023
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 41 (1) , 32-41
Hereditary succinate dehydrogenase-deficient renal cell carcinoma
- 8 November 2023
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 41 (1) , 32-41
Hereditary succinate dehydrogenase-deficient renal cell carcinoma
- Open Access
Intraductal Carcinoma of the Prostate: To Grade or Not to Grade
Intraductal carcinoma of the prostate (IDC-P) is a distinct tumor type characterized by an expansile growth of atypical glandular epithelial cells within pre-existing prostate glands and ducts and has significant implications on clinical outcomes and patient management. There is an agreement that isolated IDC-P should not be graded, and IDC-P should be reported with a comment on its clinical significance. However, whether IDC-P should be factored into Grade Group (GG) in the presence of concurrent prostate cancer (PCa) has been debated vigorously. The contradicting opinions were promulgated when the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP) published their recommendations for this issue. When IDC-P is present with PCa, the ISUP recommends incorporating it in the GG for the entire case, whereas the GUPS recommends excluding it from the final GG. Consequently, pathologists and clinicians are faced with the conundrum of conflicting recommendations. In this review article, the authors evaluate the magnitude of discrepant GG between the two grading methods, explore the rationales behind the differing views of the two urological societies, present the current reporting practices for IDC-P, and propose a provisional and pragmatic guide to alleviate the dilemma of which recommendation to follow.
Open AccessIntraductal Carcinoma of the Prostate: To Grade or Not to Grade
Intraductal carcinoma of the prostate (IDC-P) is a distinct tumor type characterized by an expansile growth of atypical glandular epithelial cells within pre-existing prostate glands and ducts and has significant implications on clinical outcomes and patient management. There is an agreement that isolated IDC-P should not be graded, and IDC-P should be reported with a comment on its clinical significance. However, whether IDC-P should be factored into Grade Group (GG) in the presence of concurrent prostate cancer (PCa) has been debated vigorously. The contradicting opinions were promulgated when the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP) published their recommendations for this issue. When IDC-P is present with PCa, the ISUP recommends incorporating it in the GG for the entire case, whereas the GUPS recommends excluding it from the final GG. Consequently, pathologists and clinicians are faced with the conundrum of conflicting recommendations. In this review article, the authors evaluate the magnitude of discrepant GG between the two grading methods, explore the rationales behind the differing views of the two urological societies, present the current reporting practices for IDC-P, and propose a provisional and pragmatic guide to alleviate the dilemma of which recommendation to follow.
- Open Access
- 7 October 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 103 (12) , 100257
Evaluation of A Computer-Aided Detection Software for Prostate Cancer Prediction: Excellent Diagnostic Accuracy Independent of Preanalytical Factors
- 7 October 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 103 (12) , 100257
Open AccessEvaluation of A Computer-Aided Detection Software for Prostate Cancer Prediction: Excellent Diagnostic Accuracy Independent of Preanalytical Factors
- 1 July 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (1) , 23-25
Point-Counterpoint: Grade Group 1 (Gleason Score 6) Prostate Cancer Should Be Renamed to Improve Public Health: Pathologists’ Perspective
- 1 July 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (1) , 23-25
Point-Counterpoint: Grade Group 1 (Gleason Score 6) Prostate Cancer Should Be Renamed to Improve Public Health: Pathologists’ Perspective
- Open Access
- 16 January 2023
- Published by Siapec Servizi Srl in Pathologica
- Vol. 115 (1) , 1-16
Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?
In 2022, after a six-year interval, the International Agency for Research on Cancer (IARC) has published the 5th edition of the WHO Classification of Urinary and Male Genital Tumors, which provides a comprehensive update on tumor classification of the genitourinary system. This review article focuses on prostate carcinoma and underscores changes in the prostate chapter as well as those made across the entire series of the 5th edition of WHO Blue Books. Although no major alterations were made to this chapter, some of the most notable updates include restructure of contents and introduction of a new format; standardization of mitotic counts, genomic nomenclatures, and units of length; refined definition for the terms “variant”, “subtype”, and “histologic pattern”; reclassification of prostatic intraepithelial neoplasia (PIN)-like adenocarcinoma as a subtype of prostatic acinar adenocarcinoma; and recognition of treatment-related neuroendocrine prostatic carcinoma as a distinct tumor type. Evolving and unsettled issues related to grading of intraductal carcinoma of the prostate and reporting of tertiary Gleason pattern, the definition and prognostic significance of cribriform growth pattern, and molecular pathology of prostate cancer will also be covered in this review.
- 16 January 2023
- Published by Siapec Servizi Srl in Pathologica
- Vol. 115 (1) , 1-16
Open AccessProstate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?
In 2022, after a six-year interval, the International Agency for Research on Cancer (IARC) has published the 5th edition of the WHO Classification of Urinary and Male Genital Tumors, which provides a comprehensive update on tumor classification of the genitourinary system. This review article focuses on prostate carcinoma and underscores changes in the prostate chapter as well as those made across the entire series of the 5th edition of WHO Blue Books. Although no major alterations were made to this chapter, some of the most notable updates include restructure of contents and introduction of a new format; standardization of mitotic counts, genomic nomenclatures, and units of length; refined definition for the terms “variant”, “subtype”, and “histologic pattern”; reclassification of prostatic intraepithelial neoplasia (PIN)-like adenocarcinoma as a subtype of prostatic acinar adenocarcinoma; and recognition of treatment-related neuroendocrine prostatic carcinoma as a distinct tumor type. Evolving and unsettled issues related to grading of intraductal carcinoma of the prostate and reporting of tertiary Gleason pattern, the definition and prognostic significance of cribriform growth pattern, and molecular pathology of prostate cancer will also be covered in this review.
- Open Access
- 27 December 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Pathology
- Vol. 000 (000) , 000
Interobserver Reproducibility of Quantifying Gleason Pattern 4 Cancer in Prostate Biopsy: Implications for Clinical Practice
The quantity of Gleason pattern (GP) 4 in Grade Group 2 prostate cancer (PCa) is an important prognostic factor and may influence treatment decisions. To be impactful for patient prognosis and management, GP4 quantification must be done in a uniform and reproducible way. This study investigated the interobserver reproducibility of GP4 quantification, and whether it may be affected by any histological features, including GP4 sub-patterns and tumor size.
- 27 December 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Pathology
- Vol. 000 (000) , 000
Open AccessInterobserver Reproducibility of Quantifying Gleason Pattern 4 Cancer in Prostate Biopsy: Implications for Clinical Practice
The quantity of Gleason pattern (GP) 4 in Grade Group 2 prostate cancer (PCa) is an important prognostic factor and may influence treatment decisions. To be impactful for patient prognosis and management, GP4 quantification must be done in a uniform and reproducible way. This study investigated the interobserver reproducibility of GP4 quantification, and whether it may be affected by any histological features, including GP4 sub-patterns and tumor size.
- 23 November 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (2) , 62-64
Should grade group 1 prostate cancer be reclassified as “non-cancer”? A pathology community perspective
- 23 November 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (2) , 62-64
Should grade group 1 prostate cancer be reclassified as “non-cancer”? A pathology community perspective
- 18 July 2022
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 31 (5) , 592-595
“Papillary Adenoma-like” Renal Tumor with TFE3 Gene Rearrangement, A Potential Precursor to or Early Event in the Development of TFE3 Translocation Renal Cell Carcinoma
MiT family translocation renal cell carcinomas harbor gene fusion involving members of MiT family of transcription factors. Their precursor lesions have not been identified. Herein, we report the first case of small papillary tumors morphologically resembling papillary adenomas but harboring TFE3 gene alteration. The patient was a 23-year old man with multiple small papillary tumors in the right kidney discovered following a gunshot wound injury. These lesions were < 5 mm, well-circumscribed but not encapsulated tubulopapillary proliferation lined with a single layer of cuboidal cells with WHO/ISUP grade 1 or 2 nuclei. The tumor cells were immunoreactive to PAX8, AMACR, high molecular weight cytokeratin, and keratin 7 and negative for CD10, CA9, TTF1, and cathepsin K. Morphologically and immunohistochemically, these lesions were diagnosed as papillary adenomas. TFE3 gene rearrangement was confirmed by fluorescence in-situ hybridization (FISH) using a TFE3 break-apart probe. We term these tumors “papillary adenoma-like” renal tumor with TFE3 gene rearrangement. These tumors are likely a precursor to or represent an early event in the development of TFE3 translocation renal cell carcinomas. An understanding of such tumors to translocation renal cell carcinoma progression can provide insight into the pathogenic mechanism, and ultimately aid the diagnosis and management of translocation renal cell carcinoma.
- 18 July 2022
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 31 (5) , 592-595
“Papillary Adenoma-like” Renal Tumor with TFE3 Gene Rearrangement, A Potential Precursor to or Early Event in the Development of TFE3 Translocation Renal Cell Carcinoma
MiT family translocation renal cell carcinomas harbor gene fusion involving members of MiT family of transcription factors. Their precursor lesions have not been identified. Herein, we report the first case of small papillary tumors morphologically resembling papillary adenomas but harboring TFE3 gene alteration. The patient was a 23-year old man with multiple small papillary tumors in the right kidney discovered following a gunshot wound injury. These lesions were < 5 mm, well-circumscribed but not encapsulated tubulopapillary proliferation lined with a single layer of cuboidal cells with WHO/ISUP grade 1 or 2 nuclei. The tumor cells were immunoreactive to PAX8, AMACR, high molecular weight cytokeratin, and keratin 7 and negative for CD10, CA9, TTF1, and cathepsin K. Morphologically and immunohistochemically, these lesions were diagnosed as papillary adenomas. TFE3 gene rearrangement was confirmed by fluorescence in-situ hybridization (FISH) using a TFE3 break-apart probe. We term these tumors “papillary adenoma-like” renal tumor with TFE3 gene rearrangement. These tumors are likely a precursor to or represent an early event in the development of TFE3 translocation renal cell carcinomas. An understanding of such tumors to translocation renal cell carcinoma progression can provide insight into the pathogenic mechanism, and ultimately aid the diagnosis and management of translocation renal cell carcinoma.
- Open Access
- 22 December 2020
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 145 (3) , 264-265
Molecular Biomarker Testing in Localized Prostate Cancer: The Critical Role of Pathologists
- 22 December 2020
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 145 (3) , 264-265
Open AccessMolecular Biomarker Testing in Localized Prostate Cancer: The Critical Role of Pathologists